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ABSTRACT
Proteus syndrome (PS) is a hamartomatous disorder with multisystem involvement that results from mutation in the AKT1gene. Since the symptoms 
and severity of PS are unique to each patient, diagnosis and treatment become hard for the physician. This article is concentrated upon the identification 
and recognition of specific characteristics of the disease, pathophysiology, symptoms, diagnosis, treatment and the necessity of advanced diagnosis, 
effective generalized and personalized therapy, as well as the requirement of new drugs for the management of PS. Detailed studies on the PS and 
evidence from the case reports revealed the requirement of intensive care, accurate diagnosis, and an effective treatment for each patient preferably 
patient-centric drug delivery due to the high degree of variation in the symptoms and clinical features among patients.
Keywords: Proteus syndrome, AKT1 gene, Pathophysiology, Symptoms, Diagnosis, Generalized and personalized treatment.
INTRODUCTION
Proteus syndrome (PS) is a hamartomatous disorder with 
multisystem involvement, resulting in excessive growth of body 
parts asymmetrically with high clinical variability due to the mosaic 
mutation in the AKT1 gene [1]. Complications of the disease may vary 
from benign and malignant tumors, skeletal malformations, blood 
vessel-associated abnormalities, bullous pulmonary disease, and 
certain skin lesions. Development of life-threatening conditions such 
as deep vein thrombosis and pulmonary embolism are prominent in 
PS [2]. PS stays silent in newborns and begins to exhibit the symptoms 
within 6–18 months and progresses with age. Irregularity in disease 
occurrence, inconsistency in symptoms among patients, restriction 
of the abnormal gene activity specifically to affected cells, presents 
challenges to physicians in diagnosis and treatment of PS [3]. Current 
diagnostic and treatment scenario in PS has been evaluated with the 
evidence of case reports and studies to recognize the challenges faced 
by the physicians during the diagnosis and treatment of the disease in 
different patients.
HISTORY OF PS
In the year 1983, a German Pediatrician Hans Rudolf Wiedemann named 
the disorder as PS, also called EllaProteus or elephant man disease. In 
1979, Micheal Cohen explained the disorder to the community. The 
disorder was first identified in a patient named Merrick whose head 
was about 36 inches, one of his fingers was 5 inches, and the skin was 
covered with warty growths and smelled unpleasantly. He was studied 
by Treves and brought to the meeting of the pathological society in 
London for further studies. However, Merrick declined examinations 
and presentations. His figurative distortion until the end stage did not 
help in the diagnosis of the disease. Merrick died in the year of 1890 
at the age of 27 due to suffocation caused by the weight of his head 
as he lied down [4]. In another case of a boy named Jordan 16-year-
old, PS started affecting the fingers, spine, neck, and legs which became 
severe during the age of 14. Above the knee amputation and the use 
of prosthetic legs has helped him in walking. Overgrowth of limbs, 
skin lesions, and thickening of the soles of his feet was precipitated 
by the disease [5]. In another case, a boy Sebastian from Australia 
presented distorted spine, bone overgrowth, orthopedic problems, and 
skin overgrowth [6]. The case of a 3 years and 8 months old girl with 
no family history of similar disorder demonstrated epidermal nevus, 
port-wine stains, macrodactyly with gigantism of feet, and swelling of 
abdomen and chest. During examination, she was observed with flat, 
soft, velvety, hyperpigmented linear nevus along the entire right arm 
extending to the neck, and then downward parallel to the midsignal 
line and a bluish red plague about 5 inches and 4 inches in size with 
an ill-defined border, studded with multiple, thick-walled, light- to 
dark-colored vesicles, and a few discharging serosanguinous fluids. PS 
gained wide public attention in the year 1980 after the movie called the 
elephant man [7,8].
EPIDEMIOLOGY
PS is very rare with <120 individuals confirmed affected. 
1 case/1,000,000 birth has a prevalence of PS. Males are more affected 
than females [9].
PATHOPHYSIOLOGY
PS is not caused by anything before or during pregnancy and not 
caused by any environmental exposure. The National Institute of Health 
(NIH) has recently recognized that mutation in the gene called serine/
threonine kinase AKT1 causes PS. Alteration in AKT1 is “c. 49G>A, 
p.Glu17Lys,” a “somatic-activating mutation.” NIH studies revealed 
that the mutation occurs in particular cells and restricts itself to the 
affected cells and progeny. The overgrowth switches to malignancy in 
cells by signaling pathway of phosphatidylinositol 3 kinases (PI3K)/
AKT. AKT binds to phosphatidylinositol 3,4,5-trisphosphate, a second 
messenger through its Pleckstrin homology and translocates to 
the cell membrane, where it gets activated. Activation is through 
phosphorylation at the threonine 308 by phosphoinositide-dependent 
kinase 1. Phosphorylation of serine 473 completes the activation 
process with the help of mTORC2 complex. Stimulated growth factors 
induce phosphatidylinositol 3, which in turn increases the level of 
phosphatidylinositol 4,5-bisphosphate available for AKT activation. 
This will upregulate cell growth, proliferation, and downregulate 
apoptosis [10].
According to Lindhurst et al., AKT1 mutation is found only in the affected 
tissues, not in normal ones. PS is a result of somatic mutation, only cells 
which generate from the affected cells exhibit symptoms. Mutations in the 
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developing phase have a less severe phenotype. The random nature of the 
somatic mutation exhibits in two components of PI3K signaling pathway, 
which makes PS a part of PTEN hamartoma tumor syndrome [11]. The 
diagrammatic representation of PS is given in Fig. 1.
SYMPTOMS
Symptoms and severity vary greatly from person to person. The peculiar 
characteristics of PS are the overgrowth of any tissue or organ in a 
mosaic and progressive manner. Asymmetric disproportionate growth 
of tissues causes distortion of the organ. Connective tissues, bones, fat, 
and skin have participated actively in PS. Cerebriform connective tissue 
nevi (CCTN), vascular anomalies, asymmetric overgrowth of bones, fatty 
tissue dysregulation, skin lesions with bumpy appearance, and scoliosis 
(curved spine) are prominently exhibited in PS [12]. Non-cancerous 
tumors often found in the ovarian membrane, malformation of the central 
nervous system (CNS) triggering mental disabilities, disfigurations such 
as a long face, narrow head, droopy eyelids, wide nostrils, and thickened 
skin pads on the soles of the feet are also identified in PS patients [13,14]. 
Most affected individuals are born without any noticeable symptoms. 
Overgrowth usually begins between 6 and 10 months. Brain overgrowth 
may be present at the time of birth [15]. Deep lines and overgrowth 
of soft tissues on the soles of the feet (cerebric form connective tissue 
moles on the skin) is a prominent symptom [16]. Medically, dangerous 
fat lipomas or invasive lipomas can produce large intrathoracic or intra-
abdominal lesions. Lymphatic malfunctions or port-wine stains can be 
generated by the abnormal blood or lymphatic vessels growth [17]. 
Internal organs affected are spleen and thymus, which become enlarged 
during disease progression. Learning disabilities, physical disfigurement, 
and developmental delays may also result from the AKT1 mutation. 
Affected individuals are prone to blood clots [18,19]. Predisposition 
to either benign or malignant tumors such as salivary gland tumors, 
monomorphic adenomas papillary thyroid carcinoma, breast cancer, 
and mesothelioma is more in PS. In some individuals, PS demonstrates 
its effect in almost all the organs as cystic lung disease, abnormalities 
of kidney or urinary system, and crossed eyes (benign eyeball cysts or 
tumors). Learning impairments and intelligence deficiency appears in 
specific patients [20,21]. The most life-threatening manifestations in PS 
are pulmonary embolism and deep vein thrombosis [22].
CONSULTATION
Multidisciplinary approach for consultation is advantageous over single 
physician advice. Orthopedist plays an important role in recognizing the 
functional significance of both hemihyperplasia and scoliosis. Cranial 
asymmetry otherwise known as hemifacial macrosomia can easily be 
identified by a craniofacial surgeon [23]. Furthermore, a plastic surgeon 
can do the resectioning of the cutaneous or subcutaneous lesions. CNS 
lesions, cortical overgrowth, hydrocephalus, craniofacial, and various 
surgical procedures can be addressed by a neurosurgeon with more 
accuracy. Successful evaluation of subcutaneous lesions and necessity 
of biopsies can be recognized by a dermatologist. Ocular involvement of 
the disease can be identified by an ophthalmologist. Dental anomalies 
can be treated by a dentist and malocclusion by an orthodontist. 
A geneticist can provide information regarding the diagnosis, diagnostic 
procedures, genetic mechanisms involved, and recurrence risks of the 
disease [24]. A pediatrician can evaluate the learning disabilities and 
developmental delays in a child and can include recommendations for 
therapy as well as schooling [25]
DIAGNOSIS
Physicians follow diagnostic criteria for the diagnosis of PS. The 
general criteria comprise of the identification of mosaic distribution 
(occurrence of overgrowth is restricted to the specific area of the 
body), sporadic occurrence, and progressive course of the disease [26]. 
The disease is confirmed when all three characteristics from general 
criteria, along with one manifestation from category A, two features 
from category B and three features from category C coexists. Specific 
criteria for the diagnosis of PS are mentioned in Table 1.
Fig. 1: Pathophysiology of Proteus syndrome
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Differential diagnosis
Differential diagnosis is the process of differentiating and confirming 
the presence of PS from similar disease conditions such as Maffucci 
syndrome, neurofibromatosis type 1, Parkes–Weber syndrome, and 
encephalocraniocutaneous lipomatosis [27].
Antenatal diagnosis
Prenatal testing is not performed in most of the PS cases as PS is not 
inherited.
Diagnostic tests in PS
Molecular tests employed in the diagnosis of gene mutations in 
PS include targeted analysis to identify the c.49G>A, p.Glu17Lys 
mutation. Analysis of multiple tissues, specifically punch biopsy of 
the affected area. Genomic testing is the more comprehensive analysis 
that comprises genome sequencing or exome sequencing. Invitae PS 
test is an example of the identification of AKT1 gene mutation. Other 
diagnostic techniques used are computed tomography scans, plain 
X-ray, high-resolution computed tomography (CT) scan of the lungs, 
brain, abdomen, limbs, and pelvis magnetic resonance imaging for 
ovarian masses detection [28,29]
Case studies on diagnosis
Skovby et al. (1993) studied two patients with spinal compromise in 
PS. In one of the patients, spinal stenosis resulted from an angular 
kyphoscoliosis, while in the second one, it resulted from infiltration of a 
paraspinal, intrathoracic angiolipoma [30].
Lacombe and Battin (1996) described two unrelated children 
diagnosed at birth with isolated macrodactyly. Examination showed the 
development of hemihypertrophy in both cases. The 4-year-old girl was 
observed with three dorsal angiomas. The symptoms of both of these 
patients fit the diagnostic criteria of PS [31].
De Becker et al. (2000) described a case on a 10-year-old boy with PS 
who presented pericardial effusion and hypogammaglobulinemia, with 
IgG and IgA deficiency and low levels of antibodies to pneumococcal 
and hemophilus type B polysaccharides, and lymphopenia. No cause 
was found for this immune deficiency, leading the authors to suggest 
that it may represent a hitherto unrecognized feature of PS [32].
Slavotinec (2000) reported three patients with PS who died 
suddenly from a pulmonary embolism. The first patient who was 
diagnosed with PS, at the age of 12 years, had varicose vein, portal 
vein thrombosis, right iliac vein occlusion, and recurrent pulmonary 
embolism. At the age 25, he died from pulmonary embolism. The 
second patient was a 9-year-old male who collapsed and died at 
home. An autopsy showed the cause of death as pulmonary embolism 
associated with deep vein thrombosis. The third case of a 17-year-old 
female showed a large pulmonary embolus with no identified deep 
vein thrombosis in autopsy when the sudden death happened during 
sinusitis treatment [33].
Mohamed bhai et al. (2002) administration of misoprostol combined 
prostaglandins was reported in mother with a baby having PS at 
6 weeks’ gestation in an attempt to abort the pregnancy [34].
Valéra et al. (2015) studied a case of a girl diagnosed with PS when she 
was 7. Even though fetal karyotyping was done during pregnancy stage, 
no abnormalities were found. During the age of three, she was examined 
by a neurologist because of a growth on her head and low language 
skills. Even though series of DNA studies for mutation was performed 
at different age levels, it was diagnosed as PS at the age of 7[35].
Rocha et al. (2017) reported a case of a 2-year-old boy diagnosed 
with PS. During the diagnosis, specific characteristics identified were 
macromelia of the limbs, syndactyly of the toes, and a wide gap between 
the toes. Prominent skin folding, irregular adipose tissue growth, and 
port-wine stains throughout the skin were seen. PS was diagnosed with 
abdomen ultrasound, Doppler echocardiography, Doppler ultrasound, 
and nuclear magnetic resonance of the skull [36].
MANAGEMENT AND TREATMENT
Physical and occupational therapy poses a major role in the treatment 
of PS. Designed orthotics such as special footwear may assist in 
walking. Rehabilitative medical care includes physical and occupational 
therapy such as correcting deformities of skeletal scoliosis. Orthopedic 
procedures help to delay or halt linear bone growth. Consideration 
of anticoagulant is a significant care, required in case of deep vein 
thrombosis or pulmonary embolism. A periodic examination can 
recognize the predisposition of tumors. Annual physical examination 
and radiography are also recommended [37]. Special care should be 
given to the dermatological abnormalities like CCTN with pedorthist 
intervention. Surgical removal of lesions is preferred if significant 
pain exists. The bullous pulmonary disease should be monitored 
continuously. Psychosocial counseling sessions are beneficial to the 
patient and family [38].
While considering the medicinal care, rapamycin in PS has found to 
have a positive potential. Another drug in Phase 1 is ARQ 092 inhibitor. 
The research has been performed by a team in the National Human 
Genome Research Institute at the US NIH [39]. Different treatments in 
PS are specified in Fig. 2.
Generalized treatment
Medical care
There is no approved drug for the treatment of PS. Existing treatments 
are only for the symptomatic relief of the disease. Rapamycin is a drug 
of choice in the treatment of PS which has been used as an effective 
immunosuppressant [40]. Mutation in the AKT1 gene provides an 
advantage of cell survival through phosphatidylinositol 3-kinase which 
is the target of rapamycin. Sirolimus-(FKBP-12) complex is inactive 
Table 1: Specific criteria for the diagnosis of PS
Category A Category B Category C
Common Uncommon Common Uncommon Common Uncommon
Connective tissue 
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against calcineurin activity, the complex binds to the receptor and 
inhibits activation of a key regulatory kinase phosphatidylinositol 
3-kinase (mTOR) in mammals. Inhibition of mTOR downregulates the 
activation of 4E binding protein 1 as well as ribosomal protein S6 [41].
Rapamycin is well absorbed from the gastrointestinal (GI) tract. 14% 
Bioavailability with approximately 92% protein binding is exhibited 
by the drug. Attain tmax in 1–3 h, after oral administration. Peak blood 
concentrations of rapamycin were observed to be 12.2±6.2 and 
37.4±21 ng/mL in renal transplant patients administered 2 mg and 
5 mg, respectively, in combination with cyclosporine and corticosteroid. 
The major route of elimination is feces. The elimination half-life of 
sirolimus was found to be 62±16 h after multiple dosing in renal 
transplant patients. No information is available on the relationship 
of age to the effects of sirolimus. Rapamycin drug is a substrate for 
both cytochrome P-450, 3A4, and p-glycoprotein. Drug induction or 
inhibition can be produced by the substrates of these enzymes and 
transporter. Synergistic effect of rapamycin with cyclosporine can 
be avoided by administering rapamycin 4 h after administration of 
cyclosporine. Rapamycin tablets should be stored between 20°C and 
25°C and oral solution should be stored between 2°C and 8°C and 
protect from light [42].
Rapamycin may cause a serious viral infection of the brain that can 
lead to disability or death. Drug interactions or immunosuppression 
can worsen this condition. In case of any changes in mental state, 
problems with speech or walking, or decreased vision, consult with a 
doctor immediately because these symptoms may start and worsen 
quickly [43]. Mortality, graft rejection, and thrombosis in the hepatic 
artery are also reported in rapamycin administered patients. In liver 
transplanted and lung transplanted patients, drug can precipitate 
bronchial anastomotic dehiscence, hypersensitivity, dermatitis, 
angioedema, fluid accumulation along with wound healing impairment. 
Long-term administration can induce hypercholesteremia in patients.
Long-term rapamycin consumption increases insulin resistance. The 
research revealed both dietary restriction and rapamycin inhibited 
lipid synthesis which can cause insulin resistance. The drug metformin 
can effectively overcome the concern since it has been used in diabetic 
patients to encourage oxidation of lipid. The studies were performed 
in humans on the effectiveness of the metformin and rapamycin in the 
treatment of aging and age-associated diseases with the support of NIH. 
The case study was on a patient diagnosed with PS at 6 months of age. 
Treatment started with oral rapamycin at a low dose when he was 2. The 
drug was found to be well tolerated and caused no side effects. Within 
2 months of treatment, there was an increase in serum albumin level, 
and for 5 years, he was able to walk independently. After 17 months 
of therapy, the drug was ceased to check the reversible antitumor 
effect. 12 weeks of cessation lead to respiratory difficulties, but the 
biochemical evidence showed the resistance to growth hormone was 
not affected by rapamycin [44].
Even though drug therapy is not a part of standard PS care, studies by 
Lindhurst et al. suggested ARQ 092 as a drug for the disease. ARQ 092 
is an orally active investigational drug producing its action by inhibiting 
AKT1, 2 and 3 isoforms. The drug is currently under clinical trial phase 
1. According to the information provided by the National Institutes of 
Health Clinical Center, the dose of ARQ 092 was determined in vitro 
using the cell obtained from the PS patients’ demonstrated reduced 
AKT1 phosphorylation with less toxicity. The study results hypothesize 
that the drug dose for the PS will be lesser than the dose of drug 
required for the cancer therapy since the aim of therapy is to inhibit 
the AKT signaling rather than killing the cells. The drug has also been 
studied for its effect on overgrowth diseases or vascular anomalies [45].
Surgical care
Surgical resectioning or even amputation is preferred in extreme 
circumstances. Prophylactic anticoagulation prior to elective surgery 
has been suggested by clinicians. For cosmetically important regions, 
plastic surgery is recommended. Subcutaneous lesions should be 
treated immediately once it starts to obstruct vision or impinging vital 
structures [46]. The size of the lipomatous lesions can be reduced 
employing laser lipolysis. This gives an advantage over surgical 
liposuction. Surgical resection may be helpful to prevent cystic lung 
malformations. The risk of the surgery includes the blood clot in 
veins, bleeding, adverse reaction to anesthesia, and overall risk of 
death [47]. Wenz and Berrsche studied different surgical cases of foot 
and ankle in PS. He has found that most of the surgical procedures such 
as osteotomies, soft-tissue resection, partial amputation, etc., were 
effective and patients were able to manage the normal functioning after 
surgery with the assistance of custom-made shoes [48].
Personalized treatment
The pattern of mutation in AKT1 gene, the cells affected by the 
mutation and the stage at which the mutation occurs determine 
the severity and the symptoms. The uniqueness of manifestations 
among the patients necessitates patient-centered therapy in PS. Early 
diagnosis of serious medical problems and the use of prophylactic and 
symptomatic treatment for functional improvement is the mainstay of 
PS. Epiphysiodesis may be especially useful to a patient with skeletal 
overgrowth. Medical approaches such as hemihyperplasia is limited to 
functional improvement. Macrodactyly impairs the normal functioning 
of hands and foot. Dental occlusion and mastication difficulties can 
be treated according to the patient concern. Hemifacial macrosomia 
or macroglossia is effective when cosmetic concerns of a patient 
are affected. Facial dysmorphism in a patient can be addressed by a 
maxillofacial surgeon or craniofacial team. Patients with lipomas and 
vascular malformations, postulate periodic evaluations throughout 
their life. Laser therapy is effective in the removal of cutaneous vascular 
Fig. 2: Treatment of proteus syndrome
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markings and malformations. Permanent removal of melanin-related 
hyperpigmentation is not possible with laser therapy. Approaches 
comprising CO2 or ruby lasers, dermatome excision followed by 
phenol peel, cryotherapy, etc., are found to be effective in individual 
patients in various degrees. Management of thrombosis is an important 
consideration due to its life threating effects in patients with a palpable 
cord and respiratory distress. The risk of thrombosis is a major concern 
before surgery [4].
RELATED DISORDERS OF PS
Hemihyperplasia, a multiple lipomatosis syndrome, characterized by 
the formation of multiple tumors of fatty tissues and the abnormal 
enlargement of either sides of the body (asymmetrical growth). 
Hemihyperplasia may indicate asymmetry between one limb and 
another or between one half of the body and the other. Encephalocranio 
cutaneous lipomatosis is an extremely rare disorder characterized by 
eye and skin abnormalities including tumors of fatty tissues. Lipomatosis 
affects the scalp and central nervous system. Skin lesions consisting 
of abnormal connective tissues development are also manifested 
in encephalocranio cutaneous lipomatosis. Some individuals have 
normal intelligence while others may experience intellectual disability. 
Seizures and porencephalic cysts have also reported in several cases. 
Klippel-Trenaunay syndrome is identified by the presence of a capillary 
port wine stain on the skin with hypertrophy of the soft tissue, bone of 
that leg or arm. Maffucci syndrome, a PS related disorder characterized 
by benign cartilage overgrowths, skeletal deformities, and patches of 
skin as a result of cutaneous benign growths of blood vessels. Maffucci 
syndrome is inherited as an autosomal dominant trait [49-51].
CASE REPORTS
A case in China has been reviewed by Zhang et al. The case presents 
a 16-year-old girl with facial dysmorphism and verrucous hyperplasia 
on the right side of her body. She was deaf and exhibited more 
abnormalities as she grew. The physical examination unveils that she 
had a normal intelligence but several anomalies. CT scan of her head 
and face showed large lipomas. ECG and ultrasound for organs were 
normal [52].
Keerthi Talari, Praveenkumar, Arinaganhali, Subramanyam 
Dharanitragada Krishna presents a case of 50-year-old man with angina 
pain. They noticed the enlargement of his index and middle fingers of 
both hands and found that he had it from the age of 5. Hypertrophy 
of fingers limited normal functioning. His systemic examination was 
otherwise normal.
Article by Popescu et al. presented a case of a years old boy who has 
suffered from a disproportionate asymmetrical overgrowth of lower 
limbs, feet, right calf, and thigh. His facial phenotype was normal. 
In the anterior part of the calf, two hard masses were identified 
by ultrasound. Under general anesthesia, an excision of the fatty 
overgrowth and lymphangioma of the posterior part of the right calf 
were performed [53].
A report by Ou et al. was about a 34-year-old man in Europe. The 
patient was admitted to Shenzhen hospital for the treatment of post-
nasal overgrowth and skin problems in the limbs and hips. The affected 
tissue samples were collected from the patient for molecular biological 
analysis by whole-exome sequencing. Results were positive for PS. The 
patient refused surgery and treatment was given to control the skin 
and GI symptoms. Treatment included mupirocin for infection of skin 
lesions. Condition remained stable and the symptoms were partially 
controlled by the treatment [54].
A case report review by Satter presents a 19-year-old man from Nias 
Island in Indonesia. The patient had an enlargement of the left foot 
and vascular lesions on his left calf from the time of his birth but did 
not notice the foot size until it became thick and resulted in pain and 
difficulties in walking. Due to the vascular malformation, there was an 
increase in his foot growth at age 7. A plain lateral radiograph of foot 
confirmed the enlargement of bones.
Satter presents another case of a 10-year-old boy with vascular lesions 
on his right chest. During the examination, the physician observed 
asymmetrical enlargement on his chest and vascular malformation 
extended up to the upper abdomen and flank. In addition, cervical 
scoliosis and multiple large lipomas on his back were also identified [55].
This report done by Vasquez et al. presents a female patient from a third 
pregnancy. The girl was diagnosed with an abnormal size of inferior 
limbs and asymmetric finger growth at the month of 5. She required 
amputation at a month of 12. On clinical criteria of diagnosis, category 
A, a genetic study of two affected tissues were performed looking 
for mutation of AKT1 gene and the results were negative for AKT1 
mutation. Ultrasound image showed a right solid paraovarian mass 
at 20 months of age when painless vaginal bleeding was noticed. The 
test was positive for tumor cells, but no other abnormal pathological 
findings were found. Post-operatory evolution was favorable and 
received three adjuvant chemotherapies in every 21 days for 3 h. The 
patient was alive till 2 years with no evidence of disease [56].
Ference et al. studied a case on rehabilitation in PS where a 23-year-
old female had a stable kyphoscoliosis amputation due to the large 
growth of both legs. She suffered from abnormal sensation, back and 
leg pain that disabled her from walking to a long distance. She was 
provided with the wheelchair for assistance. Her kyphoscoliosis was 
evaluated by an orthopedic spine surgeon. Even though non-surgical 
options such as shoe lifts to improve normal functioning are suggested, 
a patient with PS requires surgical procedures to minimize orthopedic 
deformities [57].
CONCLUSION
The absence of a specific pattern in the mutation in the AKT1 gene 
results in patient to patient variability in the disease symptoms. 
Difficulty in the identification of the mutated gene in the studies and 
the absence of proper diagnostic testing delay the confirmation of 
the disease at its early stages. This risk is especially great when the 
condition is polymorphous and variable in its expression and possibly 
falls under different medical disciplines. About 200 cases of PS have 
been reported in the literature, yet the incidence of symptoms like 
ocular malformations has not known. Under such circumstances, 
important single observations need to be reported and studied. Patient-
centric therapy, care, and new drugs are required for the effective 
treatment of PS.
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